Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2025
Event: Entry into a Material Definitive Agreement for a Private Placement of securities.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than operational financial results. Key transaction metrics include:
- Aggregate Gross Proceeds: Approximately $80 million (before offering expenses).
- Securities Issued: 5,243,732 Units.
- Unit Composition: Each Unit consists of (i) one share of Class A Common Stock or a Pre-Funded Warrant, and (ii) one Common Warrant.
- Price Per Unit: $15.265 for Units with Common Stock; $15.255 for Units with Pre-Funded Warrants.
- Warrant Exercise Price: $22.71 (for Common Stock) or $22.70 (for Pre-Funded Warrants).
- Warrant Expiration: The earlier of the fifth anniversary of issuance or 90 days following the announcement of positive top-line data from the CATT1 clinical trial.
- Expected Closing Date: September 3, 2025.
Note: The filing does not provide current revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement and a Registration Rights Agreement with institutional accredited investors.
- Beneficial Ownership Limitation: Warrant holders cannot exercise if it results in beneficial ownership exceeding 4.99% or 9.99% (adjustable up to 19.99% with 61 days' notice).
- Registration Rights: The Company must file a shelf registration statement within 30 days of closing and use commercially reasonable efforts to have it effective within 60 days (or 90 days if reviewed by the SEC).
- Liquidated Damages: If registration requirements are not met, Purchasers may be entitled to damages up to 3.0% of the aggregate price paid for Units.
Outlook, Risks, and Contingencies
Outlook: The capital raise is intended to support ongoing operations, specifically the CATT1 clinical trial, which serves as a trigger for warrant expiration.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to customary closing conditions.
- Dilution: The issuance of shares and warrants will increase the number of outstanding shares, potentially diluting existing shareholders.
- Regulatory Timing: Failure to meet registration statement deadlines could result in financial penalties (liquidated damages).
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received on or after September 3, 2025.
- Confirm the exact split between Units containing Common Stock versus Pre-Funded Warrants to assess immediate dilution.
- Monitor the status of the CATT1 clinical trial, as positive top-line data will accelerate warrant expiration.
- Review the filed Exhibits 10.1 (Securities Purchase Agreement) and 10.2 (Registration Rights Agreement) for specific covenants and indemnification terms.
- Check subsequent filings for the effectiveness of the shelf registration statement required within 60-90 days of closing.